Key Insights
The Drug-Eluting Stent (DES) market, valued at approximately $6.35 billion in 2025, is projected for substantial expansion. This growth is primarily fueled by the rising incidence of coronary artery disease (CAD) and peripheral artery disease (PAD), alongside continuous advancements in stent technology enhancing patient outcomes. The projected 8.3% compound annual growth rate (CAGR) from 2025 to 2033 underscores this significant market increase, driven by an aging global population and their increased vulnerability to cardiovascular conditions. Innovations such as bioabsorbable DES and drug-coated balloons are further accelerating market growth by providing less invasive and more effective treatment alternatives to traditional bare-metal stents. However, factors like high procedure costs, potential complications (thrombosis, restenosis), and the emergence of alternative therapies may temper market expansion. The market is segmented by coating type (polymer-based and polymer-free) and application (CAD and PAD), with CAD currently leading in market share due to its higher prevalence and established treatment protocols. North America and Europe are expected to maintain dominant market positions due to advanced healthcare infrastructure and high DES adoption rates. Conversely, the Asia-Pacific region is poised for significant growth, driven by increased healthcare expenditure and growing awareness of cardiovascular diseases. Key industry players, including Abbott Laboratories, Boston Scientific, and Medtronic, are actively engaged in research and development to secure their competitive advantage in this dynamic market.
Drug Eluting Stent Industry Market Size (In Billion)
The competitive environment features a blend of established multinational corporations and emerging regional entities. Intense competition is fostering innovation and technological progress, leading to improved stent designs with reduced complications and enhanced efficacy. Strategic collaborations, mergers and acquisitions, and the introduction of novel DES technologies are anticipated to shape future market dynamics. The trend towards minimally invasive procedures and the increasing preference for polymer-free stents present new opportunities for market participants. Ongoing research into biocompatible materials and the development of personalized medicine approaches will also significantly influence the DES market's trajectory. Effective marketing strategies and enhanced physician education on the benefits of DES over conventional treatments will be critical for sustained market growth.
Drug Eluting Stent Industry Company Market Share
This comprehensive report offers an in-depth analysis of the Drug-Eluting Stent (DES) industry, detailing market size, segmentation, growth drivers, challenges, and key players. Covering the period from 2019 to 2033, with a specific focus on the forecast period of 2025-2033 and a base year of 2025, it provides actionable insights for industry stakeholders, including manufacturers, investors, and healthcare professionals.
Drug Eluting Stent Industry Market Concentration & Innovation
The Drug Eluting Stent (DES) market exhibits a moderately concentrated landscape, with a few major players holding significant market share. However, the presence of numerous smaller companies and emerging players indicates a dynamic competitive environment. Market concentration is expected to remain relatively stable, with some potential shifts due to mergers and acquisitions (M&A) activity and the introduction of innovative products. The industry is driven by continuous innovation, particularly in areas such as bioabsorbable polymers, drug delivery systems, and stent design. Regulatory frameworks, such as those set by the FDA and other global health agencies, play a crucial role in shaping the market. These frameworks necessitate rigorous testing and approvals for new DES products.
The presence of alternative treatments, such as balloon angioplasty and other minimally invasive procedures, poses a competitive challenge. End-user trends, such as an aging population and the increasing prevalence of cardiovascular diseases, are driving market growth.
M&A activity in the DES market has been moderately active. While precise deal values are unavailable for all transactions, several transactions involving hundreds of Millions of dollars have taken place in recent years. These activities are primarily driven by strategic expansion, technology acquisition, and market consolidation.
- Market Share: Top 5 players hold approximately xx% of the market.
- M&A Activity: xx number of significant M&A deals have occurred between 2019-2024, with estimated values exceeding xx Million.
- Innovation Drivers: Bioabsorbable polymers, advanced drug coatings, improved stent design, and minimally invasive procedures.
- Regulatory Landscape: Stringent regulations impacting product approval and market entry.
Drug Eluting Stent Industry Industry Trends & Insights
The global Drug Eluting Stent (DES) market is experiencing significant growth, driven by several key factors. The rising prevalence of cardiovascular diseases, particularly coronary artery disease (CAD), is a primary driver, fueled by lifestyle changes, aging populations, and improved diagnostic capabilities. Technological advancements, such as the development of bioabsorbable polymer drug-eluting stents (BP-DES) and drug-coated balloons (DCBs), are revolutionizing the field, leading to improved patient outcomes and reduced complications. These innovations cater to the increasing demand for less invasive procedures and improved long-term results.
Consumer preference is shifting towards less invasive procedures with quicker recovery times and reduced side effects, boosting the adoption of advanced DES technologies. The competitive landscape is marked by intense rivalry among major players. This competition drives innovation and enhances market penetration, ensuring the continued development of safer and more effective DES products. The market is expected to witness a Compound Annual Growth Rate (CAGR) of xx% during the forecast period (2025-2033). Market penetration for DES is expected to reach xx% by 2033.
Dominant Markets & Segments in Drug Eluting Stent Industry
The North American region currently dominates the DES market, driven by factors such as high healthcare expenditure, advanced medical infrastructure, and a high prevalence of cardiovascular diseases. However, Asia-Pacific is witnessing rapid growth due to increasing awareness, rising disposable incomes, and expanding healthcare infrastructure.
By Coating: Polymer-based coatings currently hold the largest market share due to their established efficacy and wide availability. However, the non-biodegradable polymer-free coating segment is expected to witness significant growth due to ongoing research and development.
By Application: Coronary Artery Disease (CAD) dominates the application segment, accounting for the largest share. However, the Peripheral Artery Disease (PAD) segment is expected to exhibit considerable growth, fueled by an increasing prevalence of PAD and technological advancements that extend the applications of DES to peripheral arteries.
Key Drivers for Dominance:
- North America: High healthcare expenditure, advanced medical infrastructure, high prevalence of cardiovascular diseases.
- Asia-Pacific: Rising awareness, increasing disposable incomes, expanding healthcare infrastructure.
- Polymer-Based Coatings: Established efficacy, wide availability.
- Coronary Artery Disease: High prevalence of the condition.
Drug Eluting Stent Industry Product Developments
Recent advancements in drug-eluting stent technology focus on minimizing adverse effects and improving long-term outcomes. Bioabsorbable polymer stents are gaining popularity due to their potential to eliminate the long-term risk of late thrombosis associated with permanent metallic implants. The development of thinner struts and improved drug delivery systems further enhances the safety and efficacy of DES. These innovations improve patient compliance and offer competitive advantages by allowing for superior outcomes with minimal side effects.
Report Scope & Segmentation Analysis
This report segments the Drug Eluting Stent market based on coating type (Polymer Based Coating, Non-biodegradable Polymer Free Coating) and application (Coronary Artery Disease, Peripheral Artery Disease). Each segment is analyzed to provide insights into market size, growth projections, and competitive dynamics. The Polymer Based Coating segment is currently the largest, with substantial growth expected in the forecast period. The Non-biodegradable Polymer Free Coating segment is anticipated to show high growth due to ongoing research and development. Within applications, Coronary Artery Disease (CAD) holds the largest market share, however, Peripheral Artery Disease (PAD) is projected to experience significant growth.
Key Drivers of Drug Eluting Stent Industry Growth
Several factors contribute to the growth of the DES market. Technological advancements like bioabsorbable polymers and improved drug delivery mechanisms are improving patient outcomes. The rising prevalence of cardiovascular diseases, particularly among aging populations, fuels market demand. Favorable regulatory environments and increased healthcare expenditure in developed and emerging economies also support growth.
Challenges in the Drug Eluting Stent Industry Sector
The DES market faces several challenges. Stringent regulatory approvals and high R&D costs pose significant barriers to entry. Supply chain disruptions can impact market availability. Intense competition among established players and the emergence of alternative therapies create pressure on pricing and profit margins. The risk of adverse events, such as thrombosis, necessitates ongoing research and development to enhance safety profiles. These issues can collectively impact market growth by xx Million annually.
Emerging Opportunities in Drug Eluting Stent Industry
The DES market presents opportunities for growth. Expansion into emerging markets with high prevalence of cardiovascular diseases offers significant potential. Development of innovative drug-eluting stents with advanced materials and drug delivery mechanisms provides avenues for differentiation. Personalized medicine approaches and improved diagnostic tools can further enhance market potential.
Leading Players in the Drug Eluting Stent Industry Market
- Biosensor International (Shandong JW Medical Systems)
- AlviMedica Medical Technologies Inc
- Cook Medical
- Terumo Corporation
- Abbott Laboratories
- Stentys SA
- Medtronic Plc
- MicroPort Scientific Corporation
- Biotronik SE & Co KG
- Biosensors International Group Ltd
- Boston Scientific Corporation
- HangZhou HuaAn Biotechnology Co Ltd
Key Developments in Drug Eluting Stent Industry Industry
- May 2023: CoSo Health signed a U.S. distribution agreement with Medinol for EluNIR, a new-generation, thin-strut drug-eluting stent (DES). This significantly expands the market reach of EluNIR.
- April 2023: BIOTRONIK launched its Orsiro Mission bioabsorbable polymer drug-eluting stent system (BP-DES) in Canada. This expansion into a new market indicates increased confidence and potential for wider adoption of BP-DES technology.
Strategic Outlook for Drug Eluting Stent Industry Market
The Drug Eluting Stent market is poised for continued growth, driven by technological advancements, a growing prevalence of cardiovascular diseases, and the expansion of healthcare infrastructure in emerging economies. The focus on developing safer, more effective, and less invasive devices, along with the increasing adoption of personalized medicine approaches, presents significant opportunities for industry players to expand their market share and achieve significant revenue growth in the coming years. This continued innovation and market expansion point towards a robust and promising future for the DES industry.
Drug Eluting Stent Industry Segmentation
-
1. Coating
-
1.1. Polymer Based Coating
- 1.1.1. Biodegradable
- 1.1.2. Non-biodegradable
- 1.2. Polymer Free Coating
-
1.1. Polymer Based Coating
-
2. Application
- 2.1. Coronary Artery Disease
- 2.2. Peripheral Artery Disease
Drug Eluting Stent Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
Drug Eluting Stent Industry Regional Market Share
Geographic Coverage of Drug Eluting Stent Industry
Drug Eluting Stent Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 8.3% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rise in Geriatric Population and Increasing Prevalence of Cardiovascular Diseases; Growing Demand for Minimally Invasive Surgeries
- 3.3. Market Restrains
- 3.3.1. Strict Regulatory Approval Process of Products; Adverse Effects associated with the Drug Eluting Stents coupled with Product Recalls
- 3.4. Market Trends
- 3.4.1. Coronary Artery Disease Segment is Expected to Hold a Significant Market Share in the Drug Eluting Stent Market
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Drug Eluting Stent Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Coating
- 5.1.1. Polymer Based Coating
- 5.1.1.1. Biodegradable
- 5.1.1.2. Non-biodegradable
- 5.1.2. Polymer Free Coating
- 5.1.1. Polymer Based Coating
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. Coronary Artery Disease
- 5.2.2. Peripheral Artery Disease
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Middle East and Africa
- 5.3.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Coating
- 6. North America Drug Eluting Stent Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Coating
- 6.1.1. Polymer Based Coating
- 6.1.1.1. Biodegradable
- 6.1.1.2. Non-biodegradable
- 6.1.2. Polymer Free Coating
- 6.1.1. Polymer Based Coating
- 6.2. Market Analysis, Insights and Forecast - by Application
- 6.2.1. Coronary Artery Disease
- 6.2.2. Peripheral Artery Disease
- 6.1. Market Analysis, Insights and Forecast - by Coating
- 7. Europe Drug Eluting Stent Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Coating
- 7.1.1. Polymer Based Coating
- 7.1.1.1. Biodegradable
- 7.1.1.2. Non-biodegradable
- 7.1.2. Polymer Free Coating
- 7.1.1. Polymer Based Coating
- 7.2. Market Analysis, Insights and Forecast - by Application
- 7.2.1. Coronary Artery Disease
- 7.2.2. Peripheral Artery Disease
- 7.1. Market Analysis, Insights and Forecast - by Coating
- 8. Asia Pacific Drug Eluting Stent Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Coating
- 8.1.1. Polymer Based Coating
- 8.1.1.1. Biodegradable
- 8.1.1.2. Non-biodegradable
- 8.1.2. Polymer Free Coating
- 8.1.1. Polymer Based Coating
- 8.2. Market Analysis, Insights and Forecast - by Application
- 8.2.1. Coronary Artery Disease
- 8.2.2. Peripheral Artery Disease
- 8.1. Market Analysis, Insights and Forecast - by Coating
- 9. Middle East and Africa Drug Eluting Stent Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Coating
- 9.1.1. Polymer Based Coating
- 9.1.1.1. Biodegradable
- 9.1.1.2. Non-biodegradable
- 9.1.2. Polymer Free Coating
- 9.1.1. Polymer Based Coating
- 9.2. Market Analysis, Insights and Forecast - by Application
- 9.2.1. Coronary Artery Disease
- 9.2.2. Peripheral Artery Disease
- 9.1. Market Analysis, Insights and Forecast - by Coating
- 10. South America Drug Eluting Stent Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Coating
- 10.1.1. Polymer Based Coating
- 10.1.1.1. Biodegradable
- 10.1.1.2. Non-biodegradable
- 10.1.2. Polymer Free Coating
- 10.1.1. Polymer Based Coating
- 10.2. Market Analysis, Insights and Forecast - by Application
- 10.2.1. Coronary Artery Disease
- 10.2.2. Peripheral Artery Disease
- 10.1. Market Analysis, Insights and Forecast - by Coating
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 Biosensor International (Shandong JW Medical Systems)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 AlviMedica Medical Technologies Inc *List Not Exhaustive
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Cook Medical
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Terumo Corporation
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Abbott Laboratories
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Stentys SA
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Medtronic Plc
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 MicroPort Scientific Corporation
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Biotronik SE & Co KG
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 Biosensors International Group Ltd
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Boston Scientific Corporation
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 HangZhou HuaAn Biotechnology Co Ltd
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.1 Biosensor International (Shandong JW Medical Systems)
List of Figures
- Figure 1: Global Drug Eluting Stent Industry Revenue Breakdown (billion, %) by Region 2025 & 2033
- Figure 2: North America Drug Eluting Stent Industry Revenue (billion), by Coating 2025 & 2033
- Figure 3: North America Drug Eluting Stent Industry Revenue Share (%), by Coating 2025 & 2033
- Figure 4: North America Drug Eluting Stent Industry Revenue (billion), by Application 2025 & 2033
- Figure 5: North America Drug Eluting Stent Industry Revenue Share (%), by Application 2025 & 2033
- Figure 6: North America Drug Eluting Stent Industry Revenue (billion), by Country 2025 & 2033
- Figure 7: North America Drug Eluting Stent Industry Revenue Share (%), by Country 2025 & 2033
- Figure 8: Europe Drug Eluting Stent Industry Revenue (billion), by Coating 2025 & 2033
- Figure 9: Europe Drug Eluting Stent Industry Revenue Share (%), by Coating 2025 & 2033
- Figure 10: Europe Drug Eluting Stent Industry Revenue (billion), by Application 2025 & 2033
- Figure 11: Europe Drug Eluting Stent Industry Revenue Share (%), by Application 2025 & 2033
- Figure 12: Europe Drug Eluting Stent Industry Revenue (billion), by Country 2025 & 2033
- Figure 13: Europe Drug Eluting Stent Industry Revenue Share (%), by Country 2025 & 2033
- Figure 14: Asia Pacific Drug Eluting Stent Industry Revenue (billion), by Coating 2025 & 2033
- Figure 15: Asia Pacific Drug Eluting Stent Industry Revenue Share (%), by Coating 2025 & 2033
- Figure 16: Asia Pacific Drug Eluting Stent Industry Revenue (billion), by Application 2025 & 2033
- Figure 17: Asia Pacific Drug Eluting Stent Industry Revenue Share (%), by Application 2025 & 2033
- Figure 18: Asia Pacific Drug Eluting Stent Industry Revenue (billion), by Country 2025 & 2033
- Figure 19: Asia Pacific Drug Eluting Stent Industry Revenue Share (%), by Country 2025 & 2033
- Figure 20: Middle East and Africa Drug Eluting Stent Industry Revenue (billion), by Coating 2025 & 2033
- Figure 21: Middle East and Africa Drug Eluting Stent Industry Revenue Share (%), by Coating 2025 & 2033
- Figure 22: Middle East and Africa Drug Eluting Stent Industry Revenue (billion), by Application 2025 & 2033
- Figure 23: Middle East and Africa Drug Eluting Stent Industry Revenue Share (%), by Application 2025 & 2033
- Figure 24: Middle East and Africa Drug Eluting Stent Industry Revenue (billion), by Country 2025 & 2033
- Figure 25: Middle East and Africa Drug Eluting Stent Industry Revenue Share (%), by Country 2025 & 2033
- Figure 26: South America Drug Eluting Stent Industry Revenue (billion), by Coating 2025 & 2033
- Figure 27: South America Drug Eluting Stent Industry Revenue Share (%), by Coating 2025 & 2033
- Figure 28: South America Drug Eluting Stent Industry Revenue (billion), by Application 2025 & 2033
- Figure 29: South America Drug Eluting Stent Industry Revenue Share (%), by Application 2025 & 2033
- Figure 30: South America Drug Eluting Stent Industry Revenue (billion), by Country 2025 & 2033
- Figure 31: South America Drug Eluting Stent Industry Revenue Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Drug Eluting Stent Industry Revenue billion Forecast, by Coating 2020 & 2033
- Table 2: Global Drug Eluting Stent Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 3: Global Drug Eluting Stent Industry Revenue billion Forecast, by Region 2020 & 2033
- Table 4: Global Drug Eluting Stent Industry Revenue billion Forecast, by Coating 2020 & 2033
- Table 5: Global Drug Eluting Stent Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 6: Global Drug Eluting Stent Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 7: United States Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 8: Canada Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 9: Mexico Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 10: Global Drug Eluting Stent Industry Revenue billion Forecast, by Coating 2020 & 2033
- Table 11: Global Drug Eluting Stent Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 12: Global Drug Eluting Stent Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 13: Germany Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 14: United Kingdom Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 15: France Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 16: Italy Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 17: Spain Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 18: Rest of Europe Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 19: Global Drug Eluting Stent Industry Revenue billion Forecast, by Coating 2020 & 2033
- Table 20: Global Drug Eluting Stent Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 21: Global Drug Eluting Stent Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 22: China Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 23: Japan Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 24: India Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 25: Australia Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 26: South Korea Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 27: Rest of Asia Pacific Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 28: Global Drug Eluting Stent Industry Revenue billion Forecast, by Coating 2020 & 2033
- Table 29: Global Drug Eluting Stent Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 30: Global Drug Eluting Stent Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 31: GCC Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 32: South Africa Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 33: Rest of Middle East and Africa Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 34: Global Drug Eluting Stent Industry Revenue billion Forecast, by Coating 2020 & 2033
- Table 35: Global Drug Eluting Stent Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 36: Global Drug Eluting Stent Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 37: Brazil Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 38: Argentina Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 39: Rest of South America Drug Eluting Stent Industry Revenue (billion) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Drug Eluting Stent Industry?
The projected CAGR is approximately 8.3%.
2. Which companies are prominent players in the Drug Eluting Stent Industry?
Key companies in the market include Biosensor International (Shandong JW Medical Systems), AlviMedica Medical Technologies Inc *List Not Exhaustive, Cook Medical, Terumo Corporation, Abbott Laboratories, Stentys SA, Medtronic Plc, MicroPort Scientific Corporation, Biotronik SE & Co KG, Biosensors International Group Ltd, Boston Scientific Corporation, HangZhou HuaAn Biotechnology Co Ltd.
3. What are the main segments of the Drug Eluting Stent Industry?
The market segments include Coating, Application.
4. Can you provide details about the market size?
The market size is estimated to be USD 6.35 billion as of 2022.
5. What are some drivers contributing to market growth?
Rise in Geriatric Population and Increasing Prevalence of Cardiovascular Diseases; Growing Demand for Minimally Invasive Surgeries.
6. What are the notable trends driving market growth?
Coronary Artery Disease Segment is Expected to Hold a Significant Market Share in the Drug Eluting Stent Market.
7. Are there any restraints impacting market growth?
Strict Regulatory Approval Process of Products; Adverse Effects associated with the Drug Eluting Stents coupled with Product Recalls.
8. Can you provide examples of recent developments in the market?
In May 2023, CoSo Health signed a U.S. distribution agreement with Medinol for EluNIR, a new generation, thin-strut drug-eluting stent (DES).
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Drug Eluting Stent Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Drug Eluting Stent Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Drug Eluting Stent Industry?
To stay informed about further developments, trends, and reports in the Drug Eluting Stent Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence